Official UK procurement notice
The Guardant360 assay kits
Authority: The Royal Marsden NHS Foundation Trust (Central government)
What is being bought
Published requirement descriptionThe Guardant360 assay kits are required to deliver the Trust's partnership agreement with Guardant Health.
This is the only kit that can be used to deliver this and is included in the contract requirements with Guardant.
CPV: Pathology dissection instruments and supplies
The lotProcurement structure
single lot · no lot value publishedLot #1The G360 assay designed by Guardant Health is run using Guardant's proprietary…
The G360 assay designed by Guardant Health is run using Guardant's proprietary sequencing reagents and bioinformatics pipeline and as such an alternative sequencing assay cannot be used.
This is direct award to Guardant Health due to designed kits which are needed to run the Guardant assay.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- Price
Procedure terms & legal framework
From the official record- Procedure method
- Negotiated without publication of a contract notice
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 8 Jun 2022, 14:30 BST
- Last source update
- 8 Jun 2022, 14:30 BST
- FTS notice number
2022/S 000-015783- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-03444cFind a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to procurement aiming at the creation or acquisition of a unique work of art or artistic performance
- Published justification
There is only one supplier i.e. Guardant, we have to use their kit to run the Guardant assay, there is no alternative. We have formed a partnership with Guardant to provide this service.
Guardant360 CDx utilizes circulating tumour DNA (ctDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). Guardant360® CDx is a qualitative custom designed next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Guardant Health | £1,638,336 † | — | Awarded |
Contracts
Contract 015783-2022-1 · Guardant Health
- Signed
- 15 Oct 2021
- Value
- £1,638,336
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtMediation body
Bidders & participating suppliers
1 commercial party on the notice- Guardant HealthAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.